The board of directors of Jinxin Fertility Group Limited announced that with effect from March 28, 2021, Mr. Wang Bin has resigned as a non-executive Director, the Chairman of the Board and the chairman of the nomination committee of the Company (the "Nomination Committee"); and Mr. Zhong Ying has resigned as an executive Director of the Company due to their respective decisions to devote more time to their other commitments with the Company. Each of Mr. Wang Bin and Mr. Zhong Ying will continue to act as a member of the strategic decisions committee of the Company (the "Strategic Decisions Committee"). Each of Mr. Wang Bin and Mr. Zhong Ying has confirmed that he has no disagreement with the Board and there is no other matter relating to their resignation that needs to be brought to the attention to the shareholders of the Company (the "Shareholders") or The Stock Exchange of Hong Kong Limited (the "Stock Exchange"). The Board announced that, with effect from March 28, 2021, Dr. Geng Lihong has been appointed as an executive Director. Dr. Geng Lihong has been the chief medical quality control officer of the Company since February 21, 2020. The Board further announces that, with effect from March 28, 2021, Ms. Yan Xiaoqing has been appointed as a non-executive Director. Ms. Yan Xiaoqin has been a senior vice president of the Company since September 12, 2018. The Company further announces that, with effect from March 28, 2021, Mr. Zhong Yong has been re-designated from the Vice Chairman of the Board to the Chairman of the Board. Mr. Zhong Yong will be responsible for the overall strategic planning and future development as well as the business direction of the business operations of the Group. He will continue to act as an executive Director and the chairman of the Strategic Decisions Committee. The Board further announces that with effect from March 28, 2021, Mr. Zhong Yong, an executive Director, has been appointed as the chairman of the Nomination Committee; and Mr. Zhong Ying has been re-designated from a member to the chairman of the medical quality control and R&D committee of the Company (the "Medical Quality Control and R&D Committee").